CHORDOMA-IO-MIGLIORINI
Regimen
- Experimental
- Anti-PD-1 therapy (nivolumab or pembrolizumab) off-label compassionate-use dosing
- Control
- none (case series)
Population
Three relapsed advanced chordoma patients after failure of surgery, radiotherapy, and prior systemic therapy (including imatinib)
Key finding
First report of any clinical response to immunotherapy in chordoma. Generated the hypothesis that chordoma — despite being a low-TMB tumor — has enough PD-L1 and infiltrating lymphocytes to sometimes respond to PD-1 blockade.
Source: PMID 28919999